NVO News and Headlines - Novo Nordisk A/S

GuruFocus Articles Total 109
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6

The stock of Novo Nordisk A/S (NYSE:NVO, 30-year Financials) appears to be fairly valued, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate of the fair value at which the stock should be traded. It is calculated based on the historical multiples that the stock has traded at, the past business growth and analyst estimates of future business performance. If the price of a stock is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line,

0 Views    GF Value    2021-03-29 03:12
3 companies among those expected to learn about effectiveness of key treatments in 2021

The prospects for several drug makers—and their investors—are likely to be affected as clinical trial results for key medications are reported this year. For an example of what a bad outcome can have on a company's share price, look no further than what happened to Eli Lilly and Co.'s (LLY) stock on Monday when the Indianapolis-based pharma company reported mixed results in tests of its Alzheimer's treatment. On the news, Lilly's shares took a haircut of nearly $20 to about $188.

Eli Lilly will get a chance to redeem itself when it also gets a readout this year on its

421 Views    Barry Cohen    2021-03-16 18:58
Thermo Fisher tops the list

According to the GuruFocus All-in-One Screener, a Premium feature, the following guru-owned health care stocks have outperformed the S&P 500 Index over the past 12 months through Dec. 22.


Abbott Laboratories (ABT) has a market cap of $193 billion. It has outperformed the S&P 500 by 12.01% over the past year.

As of Tuesday, the share price was 76.87% above the 52-week low and 5.36% below the 52-week high.

The company, which manufactures medical devices and adult and pediatric nutritional products, has a GuruFocus profitability rating of 7 out of 10. The return on equity of 10.9%

158 Views    Tiziano Frateschi    2020-12-22 21:11
Company plans to apply Emisphere's know-how to more of its medications

Danish pharmaceutical giant Novo Nordisk AS (NVO) hopes to apply a unique drug delivery technology it acquired to enable people to take more of its drugs by mouth.

Novo obtains the know-how with the $1.8 billion purchase of Emisphere Technologies Inc. (EMIS), a New Jersey-based company that specializes in drug delivery. Emisphere trades over the counter.

Novo recently used the Emisphere technology under license to develop its diabetes drug, Rybelsus—the first and only oral type of a class of drugs called glucagon-like peptide agonists, according to an article in FiercePharma. GL-1 drugs not only improve blood sugar control, but may

120 Views    Barry Cohen    2020-11-12 19:40
Stocks with high Greenblatt Magic Formula rank as coronavirus pandemic surges

In light of coronavirus cases increasing both domestically and internationally, four health care companies with strong business quality are Biogen Inc. (BIIB), Novo Nordisk A/S (NVO), ResMed Inc. (RMD) and Illumina Inc. (ILMN) according to the All-in-One Screener, a Premium feature of GuruFocus.

U.S. markets slip as coronavirus cases increase around the globe

On Monday, the Dow Jones Industrial Average closed at 28,195.42, down 410.89 points from last Friday's close of 28,606.31 as surging coronavirus cases around the globe dampened investor sentiment.


According to Johns Hopkins University statistics, global cases of Covid-19

524 Views    James Li    2020-10-19 21:50
Stocks to consider as coronavirus casualties around the globe top 1 million

As the world grapples with an unprecedented coronavirus pandemic, five health care stocks that have outperformed the Standard & Poor's 500 Index by at least 5% in the year to date are AmerisourceBergen Corp. (ABC), Chemed Corp. (CHE), Neogen Corp. (NEOG), Novo Nordisk A/S (NVO) and ResMed Inc. (RMD) according to the All-in-One Screener, a Premium feature of GuruFocus.

U.S. markets slip on renewed fears of coronavirus spread

On Tuesday, the Dow Jones Industrial Average closed at 27,451.81, down 132.25 points from Monday's close of 27,584.06. The 30-stock index traded at an intraday low of 27,338 earlier in

282 Views    James Li    2020-09-29 21:47
UnitedHealth on the list

According to the GuruFocus All-in-One Screener, a Premium feature, the stocks of the following guru-owned health care companies have outperformed the S&P 500 Index over the past 12 months through July 10.


UnitedHealth Group Inc. (UNH) has a market cap of $287.94 billion. It has outperformed the S&P 500 by 7.42% over the past year.

Shares are trading with a price-earnings ratio of 7.08. As of Friday, the share price was 61.74% above the 52-week low and 3.87% below the 52-week high.

The company has a GuruFocus profitability rating of 8 out of 10. The return on

70 Views    Tiziano Frateschi    2020-08-07 15:24
During same 10-year period, Eisai and Abbott were worst performers in measure

Among the largest publicly traded pharmaceutical companies, Novo Nordisk (NVO) and Roche (RHHBY) had the highest returns on invested capital during the period from 2011 to 2019, according to a report from the Westhealth Policy Center. At the other end of the spectrum were Abbott Laboratories (ABT) and Easai Co. (TSE:4523).

In simplest terms, ROIC is a profitability ratio that indicates just how efficient a company is turning capital into profit. It measures the return that an investment generates for those who have provided capital (i.e., bondholders and stockholders).

ROIC can be important to investors because it is a key

106 Views    Barry Cohen    2020-07-28 20:35
If approved, company's Roctavian would become first gene therapy for inherited disease

Five pharmaceutical companies are awaiting approval of drugs in the next few months, and Biomarin Pharmaceutical Inc. (BMRN) has the most to gain. If the company’s Roctavian gets greenlighted by the Food and Drug Administration, it will become the first gene therapy for one of the world’s highest-profile inherited diseases, hemophilia A.

Hemophilia is a rare hereditary bleeding disorder that occurs in a relatively small number of patients around the world. Its cause is a missing or deficient protein needed for blood clotting. Hemophilia A occurs in one in 5,000 live male births. It is about four times as common

231 Views    Barry Cohen    2020-07-09 18:57
Stocks to consider as biotech company Novavax gets $1.6 billion in federal aid for Covid-19 vaccine

In light of Novavax Inc. (NVAX) getting $1.6 billion in federal aid for its coronavirus vaccine candidate, investors might find opportunities in biotechnology stocks that have high financial strength, earnings yield and return on capital. The top five stocks according to the Joel Greenblatt Magic Formula Screen, a Premium value screen, are Alexion Pharmaceuticals Inc. (ALXN), Novo Nordisk A/S (NVO), Galapagos NV (GLPG), Regeneron Pharmaceuticals Inc. (REGN) and Vertex Pharmaceuticals Inc. (VRTX).

Novavax continues big surge on coronavirus vaccine federal aid

Shares of the Gaithersburg, Maryland-based company closed at $104.56, close to a 52-week high of

765 Views    James Li    2020-07-07 21:48
Novo Nordisk A/S tops the list

Growing earnings can often push share prices up. The S&P 500 Index, which is a benchmark for the U.S. market, has grown its annual earnings per share (not adjusted for inflation) by about 6.5% every year over the past five years. On the tailwind of this, the share price of the index increased by nearly 49% over the past five years, closing at a price of $3,003.37 on March 3, 2020.

Past performance is not a guarantee of future results, but it does indicate that a company has a better foundation on which to grow.

As a result of strong

73 Views    Alberto Abaterusso    2020-03-04 17:51
When you find a company with a deep competitive moat, stick with the management team that got them there

"When you have to make a choice and don’t make it, that is in itself a choice."

- William James

One evening a Cherokee elder told his grandson about a battle that goes on inside people. He said, “My son, the battle is between two “wolves” inside us all. One is Evil. It is anger, envy, jealousy, sorrow, regret, greed, arrogance, self-pity, guilt, resentment, inferiority, lies, false pride, superiority, and ego. The other is Good. It is joy, peace, love, hope, serenity, humility, kindness, benevolence, empathy, generosity, truth, compassion, and faith.” The grandson thought about

717 Views    Thomas Macpherson    2020-01-31 16:41
Stocks to consider as China coronavirus outbreak pressures markets

In light of the coronavirus outbreak in China, five U.S. and Asian health care companies with good financial strength and profitability are Edwards Lifesciences Corp. (EW), Novo Nordisk A/S (NVO), Guangdong Zhongsheng Pharmaceutical Co. Ltd. (SZSE:002317), DongKook Pharmaceutical Co. Ltd. (XKRX:086450) and Bumrungrad Hospital PCL (BKK:BH) according to the All-in-One Screener, a major GuruFocus Premium feature.

Dow tumbles on increased coronavirus fears, suggesting opportunities in health care

On Monday, the Dow Jones Industrial Average closed at 28,533.90, down 455.83 points from Friday’s close of 28,989.73, on increased fears over the coronavirus’ impact to the global

325 Views    James Li    2020-01-27 22:00
Stocks to consider as China agrees to purchase $200 billion in US goods, including pharma

According to the All-in-One Screener, a GuruFocus Premium feature, four health care companies with high financial strength and profitability are Biogen Inc. (BIIB), Illumina Inc. (ILMN), Masimo Corp. (MASI) and Novo Nordisk A/S (NVO).

China agrees to purchase $200 billion worth of U.S. goods as part of trade deal, including pharma products

On Wednesday, Chinese President Xi Jinping and U.S. President Trump signed “phase one” of their landmark trade deal, which includes China purchasing $200 billion in U.S. goods over the next two years. Manufactured goods, which include industrial equipment, electric equipment and pharmaceutical products, account

585 Views    James Li    2020-01-15 22:50
A strategic focus, dominant positions and secular growth opportunities outweigh the general pipeline risk

Denmark-based Novo Nordisk (OCSE:NOVO B) (NVO) is a global developer of drugs to treat chronic diseases, including diabetes, obesity and hemophilia. The company has sales in 170 countries.

Diabetes and obesity together accounted for 84% of the company’s fiscal 2018 sales. The U.S. is the most significant revenue contributor (49% as of 2018 sales), followed by Europe (19%), Africa, Asia, Middle East and Oceania (11%) and China (10%). Although we are typically cautious about the pipeline risk associated with investing in pharma, we appreciate the strategic focus, dominant market positions and secular growth opportunities at Novo Nordisk.

The company dominates

678 Views    Steven Chen    2020-01-02 16:53
Sometimes the advantages that can drive long-term value erode away. When that happens, time is no longer the friend of a newly mediocre portfolio holding

"The two most powerful warriors are patience and time.” - Leo Tolstoy

Great leadership is about continual change. An outstanding leader is always seeking opportunities in failure and always seeking improvement from success. Patience is key, but does not guarantee long-term prosperity.” - Iwasaki YatarŠ

In Japan, the Sengoko period (or, as translated into English, “The Age of Warring States”) ran from roughly the mid-15th century and ended with the Battle of Sekigahara in 1603. During that time, Japan was engaged in nearly constant civil wars as a series of very powerful regional leaders known as d'imyo battled

904 Views    Thomas Macpherson    2019-11-17 21:23
Analysts set average 12-month target more than 70% above current price

Dr. Jennifer Schneider, the president of Livongo Health Inc. (LVGO), couldn’t have been more succinct in describing what the Mountain View, California-based company does: “make it easier for members to stay healthy." In doing so, the company also hopes to put its investors in the pink.

Livongo is an information technology company that uses its software platform to improve the health of patients with chronic conditions, including hypertension, diabetes and weight issues.

The company had a strong opening when it went public on July 25. Its stock climbed 60% above the initial public offering,

79 Views    Barry Cohen    2019-11-14 22:26
Paul Hudson is examining the organization from top to bottom with the goal of developing a strategy to put the company on the road to success

Sanofi SA's (SNY) newly minted CEO is looking under the hood to figure out what’s needed to get the company in gear. Shareholders are hoping he’s successful. The French pharmaceutical giant has been stuck in neutral for a while, with its shares off a few dollars from where they were two years ago. In defense of Sanofi’s performance, the stock has outperformed the SPDR S&P Pharmaceuticals Exchange-Traded Fund (XPH)

Paul Hudson, 51, who came to Sanofi from Novartis early last month, has been on what he calls a “listening tour,” site to site, country to country, according to an Oct.

208 Views    Barry Cohen    2019-10-13 20:15
European markets offer opportunities as investors await US-China trade talks

As investors anticipate the next round of trade talks between the U.S. and China, several opportunities exist in European markets. According to the High Quality Screener, one of our predefined screens within the All-in-One Screener, five European health care companies with good business quality are BioGaia AB (OSTO:BIOG B), CellaVision AB (OSTO:CEVI), Diasorin SpA (MIL:DIA), Novo Nordisk A/S (NVO)(OCSE:NOVO B) and Vitrolife AB (OSTO:VITR).

Dow trades higher, but European markets decline ahead of US-China trade talks

Although the Dow Jones Industrial Average traded at an intraday high of 26,424.31, up 260.27 points from Tuesday’s close of 26,164.04, the 30-stock

332 Views    James Li    2019-10-09 20:33
Top Berkshire holding Apple makes list

In light of rekindling trade concerns between the U.S. and China, four U.S. stocks with the financial strength and profitability to weather the storm are Apple Inc. (AAPL), Novo Nordisk A/S (NVO), Manhattan Associates Inc. (MANH) and Paychex Inc. (PAYX).

Dow tumbles as White House mulls investment ban on China

On Friday, the Dow Jones Industrial Average closed at 26,820.25, down 70.87 from Thursday’s close of 26,891.12 and 192.29 from the intraday high of 27,012.54. CNBC columnists Eamon Javers and Yun Li reported that sources familiar with the matter said the White House is “weighing some curbs on U.S. investments

598 Views    James Li    2019-09-27 20:54

Headlines Total 121
  • 1
  • 2

2021-04-13 $ 70.77 (1.89%)
2021-04-01 $ 67.66 (0.36%)
2021-03-30 $ 67.92 (-0.75%)
2021-03-19 $ 70.35 (-0.79%)
2021-03-18 $ 70.91 (-1.21%)
2021-02-26 $ 71.25 (-1.51%)
2021-02-22 $ 72.75 (-1.8%)
2021-02-19 $ 74.08 (-1.35%)
2021-02-04 $ 71.63 (-1.08%)
2021-02-03 $ 72.41 (2.03%)
2021-01-29 $ 69.6 (-1.42%)
2021-01-28 $ 70.6 (0.9%)
2021-01-27 $ 69.97 (-4.5%)
2021-01-21 $ 72.52 (0.75%)
2021-01-19 $ 73.02 (1.37%)
2021-01-13 $ 70.9 (2.26%)
2021-01-12 $ 69.33 (-1.55%)
2021-01-06 $ 68.93 (-2.6%)
2021-01-05 $ 70.77 (-0.92%)
2020-12-30 $ 70.2 (-0.54%)
2020-12-21 $ 71.9 (-2.57%)
2020-12-10 $ 69.28 (-1.38%)
2020-12-09 $ 70.25 (2.44%)
2020-12-08 $ 68.58 (0.54%)
2020-12-07 $ 68.21 (0.59%)
2020-12-01 $ 67.51 (0.57%)
2020-11-30 $ 67.13 (-0.61%)
2020-11-25 $ 66.14 (0.33%)
2020-11-18 $ 66.52 (-0.31%)
2020-11-16 $ 67.29 (-1.16%)
2020-11-12 $ 68.22 (0.77%)
2020-11-11 $ 67.7 (0.25%)
2020-11-10 $ 67.94 (-3.44%)
2020-11-09 $ 67.94 (-3.44%)
2020-11-05 $ 71.56 (2.27%)
2020-10-30 $ 63.89 (-3.68%)
2020-10-19 $ 70.78 (-0.34%)
2020-10-15 $ 70.57 (-1.62%)
2020-10-13 $ 73.18 (-0.6%)
2020-10-09 $ 72.07 (1.17%)
2020-10-06 $ 69.16 (-1.37%)
2020-10-02 $ 68.66 (-0.85%)
2020-09-21 $ 68.99 (-0.65%)
2020-09-18 $ 69.44 (-0.19%)
2020-09-16 $ 67.96 (0.06%)
2020-09-09 $ 66.65 (2.81%)
2020-09-08 $ 64.83 (-0.43%)
2020-09-04 $ 65.11 (0.05%)
2020-08-17 $ 66.86 (1.66%)
2020-08-14 $ 65.77 (-1.63%)
2020-08-13 $ 66.86 (-0.34%)
2020-08-06 $ 63.69 (-2.15%)
2020-07-28 $ 67.28 (-0.19%)
2020-07-13 $ 65.15 (-0.44%)
2020-06-22 $ 67.94 (0.58%)
2020-06-17 $ 66.72 (2.19%)
2020-06-12 $ 64.61 (0.29%)
2020-06-10 $ 66.56 (2.99%)
2020-06-01 $ 65.7 (-0.36%)
2020-05-29 $ 65.94 (1.51%)
2020-05-22 $ 64.83 (0.02%)
2020-05-13 $ 63.25 (1.14%)
2020-05-08 $ 62.76 (0.72%)
2020-05-07 $ 62.31 (0.53%)
2020-04-30 $ 63.33 (0.46%)
2020-04-29 $ 63.04 (-2.4%)
2020-04-28 $ 64.59 (-0.84%)
2020-04-21 $ 64.1 (-0.02%)
2020-04-14 $ 59.79 (1.61%)
Total 121
  • 1
  • 2